open access

Vol 49, No 3 (2011)
Original paper
Submitted: 2012-01-05
Published online: 2011-10-28
Get Citation

Different expression of cyclooxygenase-2 (COX-2) in selected nonmelanocytic human cutaneous lesions

Łukasz Kuźbicki, Dariusz Lange, Agata Stanek-Widera, Barbara W. Chwirot
DOI: 10.5603/FHC.2011.0054
·
Folia Histochem Cytobiol 2011;49(3):381-388.

open access

Vol 49, No 3 (2011)
ORIGINAL PAPERS
Submitted: 2012-01-05
Published online: 2011-10-28

Abstract

The aim of our study was to elucidate the possible involvement of COX-2 in the development and/or progression of nonmelanocytic skin lesions. To evaluate the usefulness of that enzyme as a potential molecular marker, we examined the intensity and spatial distribution of COX-2 expression in selected types of such tumors using the same immunohistochemical procedure as in our earlier studies of melanocytic cancers. We examined 20 benign epithelial lesions, 11 precancerous lesions, 21 basal cell carcinomas (BCC), 14 squamous cell carcinomas (SCC) and eight fibromas. The levels of COX-2 expression detected in benign lesions and in normal skin were comparable. Elevated expression of this protein may play a role in the development of SCC, as indicated by strong immunostaining both in SCCs and precancerous lesions. Significantly stronger staining in SCCs compared to BCCs may indicate a role of COX-2 in cancer malignancy and serve as an indicator useful for differential diagnostics of the two types of cancer. Strong staining in all skin layers of SCC may help in detecting cancer cells infiltrating surrounding skin layers. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 3, pp. 381–388)

Abstract

The aim of our study was to elucidate the possible involvement of COX-2 in the development and/or progression of nonmelanocytic skin lesions. To evaluate the usefulness of that enzyme as a potential molecular marker, we examined the intensity and spatial distribution of COX-2 expression in selected types of such tumors using the same immunohistochemical procedure as in our earlier studies of melanocytic cancers. We examined 20 benign epithelial lesions, 11 precancerous lesions, 21 basal cell carcinomas (BCC), 14 squamous cell carcinomas (SCC) and eight fibromas. The levels of COX-2 expression detected in benign lesions and in normal skin were comparable. Elevated expression of this protein may play a role in the development of SCC, as indicated by strong immunostaining both in SCCs and precancerous lesions. Significantly stronger staining in SCCs compared to BCCs may indicate a role of COX-2 in cancer malignancy and serve as an indicator useful for differential diagnostics of the two types of cancer. Strong staining in all skin layers of SCC may help in detecting cancer cells infiltrating surrounding skin layers. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 3, pp. 381–388)
Get Citation

Keywords

cyclooxygenase-2 (COX-2); nonmelanocytic skin lesions; diagnostics; tumor invasiveness; immunohistochemistry

About this article
Title

Different expression of cyclooxygenase-2 (COX-2) in selected nonmelanocytic human cutaneous lesions

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 3 (2011)

Article type

Original paper

Pages

381-388

Published online

2011-10-28

DOI

10.5603/FHC.2011.0054

Bibliographic record

Folia Histochem Cytobiol 2011;49(3):381-388.

Keywords

cyclooxygenase-2 (COX-2)
nonmelanocytic skin lesions
diagnostics
tumor invasiveness
immunohistochemistry

Authors

Łukasz Kuźbicki
Dariusz Lange
Agata Stanek-Widera
Barbara W. Chwirot

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl